Key result
Rituximab, vincristine, defibrotide, pravastatin, and eculizumab show similar response rates for TA-TMA after HSCT.
Why the study?
What are the response rates of various pharmacologic treatments for transplant-associated thrombotic microangiopathy after hematopoietic stem cell transplantation?
Population
Patients with transplant-associated thrombotic microangiopathy after hematopoietic stem cell transplantation
Design
Review
Authors
Loading...
Similar response rates leave agent choice open; hypothesis-generating and requires prospective randomized trials before practice change.
What are the response rates of various pharmacologic treatments for transplant-associated thrombotic microangiopathy after hematopoietic stem cell transplantation?
Various pharmacologic agents show similar response rates (69-80%) for TA-TMA after HSCT, but larger studies are needed to establish definitive treatment strategies.
Kim et al. (2014) conducted a review in Transplant-associated thrombotic microangiopathy (TA-TMA). Pharmacologic agents (rituximab, vincristine, defibrotide, pravastatin, eculizumab) was evaluated on Overall response rate. Pharmacologic agents including rituximab, vincristine, defibrotide, pravastatin, and eculizumab demonstrated similar overall response rates (69%-80%) for treating TA-TMA after HSCT.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: